Orgenesis Inc (ORGS) - Total Assets
Based on the latest financial reports, Orgenesis Inc (ORGS) holds total assets worth $29.69 Million USD as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Orgenesis Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Orgenesis Inc - Total Assets Trend (2008–2023)
This chart illustrates how Orgenesis Inc's total assets have evolved over time, based on quarterly financial data. See Orgenesis Inc (ORGS) shareholders funds for net asset value and shareholders' equity analysis.
Orgenesis Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Orgenesis Inc's total assets of $29.69 Million consist of 28.0% current assets and 72.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.8% |
| Accounts Receivable | $88.00K | 0.6% |
| Inventory | $34.00K | 0.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.38 Million | 50.7% |
| Goodwill | $1.21 Million | 8.3% |
Asset Composition Trend (2008–2023)
This chart illustrates how Orgenesis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Orgenesis Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orgenesis Inc's current assets represent 28.0% of total assets in 2023, a decrease from 100.0% in 2008.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2023, down from 100.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 58.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 50.7% of total assets.
Orgenesis Inc Competitors by Total Assets
Key competitors of Orgenesis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Orgenesis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.61 | 0.82 |
| Quick Ratio | 0.07 | 0.61 | 0.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-33.53 Million | $-5.53 Million | $-5.60 Million |
Orgenesis Inc - Advanced Valuation Insights
This section examines the relationship between Orgenesis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.26 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | -84.0% |
| Total Assets | $14.55 Million |
| Market Capitalization | $9.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Orgenesis Inc's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Orgenesis Inc's assets decreased by 84.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Orgenesis Inc (2008–2023)
The table below shows the annual total assets of Orgenesis Inc from 2008 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $14.55 Million | -84.00% |
| 2022-12-31 | $90.93 Million | +51.95% |
| 2021-12-31 | $59.84 Million | -22.97% |
| 2020-12-31 | $77.68 Million | -16.01% |
| 2019-12-31 | $92.50 Million | +22.60% |
| 2018-12-31 | $75.45 Million | 0.00% |
| 2018-11-30 | $75.45 Million | +89.22% |
| 2017-12-31 | $39.87 Million | +19.07% |
| 2016-12-31 | $33.49 Million | -13.58% |
| 2015-12-31 | $38.75 Million | +1622.94% |
| 2014-12-31 | $2.25 Million | +1868.95% |
| 2013-12-31 | $114.22K | +137.14% |
| 2012-12-31 | $48.17K | +1958.42% |
| 2011-12-31 | $2.34K | +44.71% |
| 2010-12-31 | $1.62K | -94.92% |
| 2009-12-31 | $31.85K | -42.09% |
| 2008-12-31 | $55.00K | -- |
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of res… Read more